Literature DB >> 10522764

Will cancer risk assessment and counseling services survive genetic testing?

P T Kelly1.   

Abstract

With the availability of genetic testing to detect increased hereditary susceptibility to breast and other cancers, Cancer Risk Assessment and Counseling services have come to be viewed by many primarily as a means of obtaining genetic testing and hereditary risk information. The public and healthcare professionals need to be aware that even when genetic testing is not used or is uninformative, families with and without a strong family history of cancer will benefit from Cancer Risk Assessment and Counseling if the process includes assessment of cancer risk, information about cancer etiology, help in dealing with the psychosocial consequences of the cancer experience, and development of emotional and medical coping strategies. Risk assessment services can best serve concerned individuals and their families when sufficient time is allotted for these primary aims, and when genetic testing is seen as one of the useful tools, not the primary goal of such services.

Entities:  

Mesh:

Year:  1999        PMID: 10522764     DOI: 10.1080/028418699432897

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  3 in total

1.  Differences in individual approaches: communication in the familial breast cancer consultation and the effect on patient outcomes.

Authors:  Elizabeth A Lobb; Phyllis Butow; Alexandra Barratt; Bettina Meiser; Katherine Tucker
Journal:  J Genet Couns       Date:  2005-02       Impact factor: 2.537

2.  A randomized trial of specialist genetic assessment: psychological impact on women at different levels of familial breast cancer risk.

Authors:  K Brain; P Norman; J Gray; C Rogers; R Mansel; P Harper
Journal:  Br J Cancer       Date:  2002-01-21       Impact factor: 7.640

3.  Communication and information-giving in high-risk breast cancer consultations: influence on patient outcomes.

Authors:  E A Lobb; P N Butow; A Barratt; B Meiser; C Gaff; M A Young; E Haan; G Suthers; M Gattas; K Tucker
Journal:  Br J Cancer       Date:  2004-01-26       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.